 A 12 WEEK TREATMENT, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO AND ACTIVE CONTROLLED STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF INDACATEROL MALEATE GLYCOPYRRONIUM BROMIDE IN COPD PATIENTS WITH MODERATE TO SEVERE AIRFLOW LIMITATION.: 